Publications by authors named "Jill Kaufman"
Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis.
J Comp Eff Res
December 2024
Article Synopsis
- In rheumatoid arthritis, having both anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) indicates more severe disease and can affect treatment outcomes; abatacept is a recommended biologic treatment for those who don't respond to traditional medications.
- A study tracking 296 RA patients treated with abatacept showed significant improvement in clinical disease activity over 12 months, with mean disease activity scores decreasing by up to 74% after treatment.
- Among patients who initially had high disease activity, about 71% achieved low disease activity or remission during the follow-up, and serious adverse events were reported in only 2.4% of cases, highlighting abatacept's effectiveness and safety.
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm with a prevalence of 4 to 6 per 100,000 people in the USA. Treatment recommendations are risk-adapted. This study was conducted to evaluate how physicians risk-stratify patients at the time of MF diagnosis, the accuracy of the risk stratification, and its effect on treatment selection.
View Article and Find Full Text PDFEffective physician workforce management requires that the various organizations comprising the House of Medicine be able to assess their current and future workforce supply. This information has direct relevance to funding of graduate medical education. We describe a dynamic modeling tool that examines how individual factors and practice variables can be used to measure and forecast the supply and demand for existing and new physician services.
View Article and Find Full Text PDFContext: Genomic sequencing for cancer is offered by commercial for-profit laboratories, independent laboratory networks, and laboratories in academic medical centers and integrated health networks. The variability among the tests has created a complex, confusing environment.
Objective: To address the complexity, the Personalized Health Care (PHC) Committee of the College of American Pathologists proposed the development of a cancer genomics resource list (CGRL).
Purpose: The practice of "genomic" (or "personalized") medicine requires the availability of appropriate diagnostic testing. Our study objective was to identify the reasons for health systems to bring next-generation sequencing into their clinical laboratories and to understand the process by which such decisions were made. Such information may be of value to other health systems seeking to provide next-generation sequencing testing to their patient populations.
View Article and Find Full Text PDF